| Similar Articles |
|---|
 |
Fast Company
September 2004
Linda Tischler |
The Trials of ImClone A founder in handcuffs, financials in disarray, and a vital product in doubt-for CEO Daniel Lynch, it was the turnaround from hell.   |
BusinessWeek
March 8, 2004
Arnst & Ewing |
The Odyssey Of A Cancer Drug How ImClone overcame scandal and FDA objections to get Erbitux to market |
The Motley Fool
February 12, 2004
Bill Mann |
ImClone's Mysterious Plunge Investors flee the stock the instant before it receives great news. Oops. |
The Motley Fool
June 12, 2007
Brian Lawler |
ImClone Tries To Improve Erbitux ImClone is running trials to see if the drug can be used in earlier stages of cancer. Investors shouldn't discount the importance of an approved drug's product label. |
The Motley Fool
July 20, 2006
Brian Lawler |
No Surprises From ImClone ImClone's lead product experienced strong revenue growth in the second quarter. But biotech investing is fraught with risk. Investors, take note. |
The Motley Fool
July 16, 2007
Brian Lawler |
Slight Setback for ImClone ImClone announces a failed cancer study. Investors, take note. |
The Motley Fool
September 1, 2004
Bill Mann |
Triumph of Hope Over Reason A frighteningly expensive drug of marginal efficacy begets triple-digit multiples? Bring on the miracles. Standard & Poor's reiterated its "buy" rating of ImClone. |
Fast Company
December 2005
Keith H. Hammonds |
A Bear Market for Courage A retrospective look at courageous businesses noted in 2004. |
The Motley Fool
June 4, 2008
Brian Lawler |
Erbitux's Deceptively Disappointing Results Poorly received lead-drug data batters ImClone shares. |
The Motley Fool
April 5, 2007
Brian Lawler |
ImClone Steps to the Front ImClone announces a successful clinical trial for the cancer drug Erbitux. Investors, take note. |
The Motley Fool
April 27, 2007
Brian Lawler |
Tracking ImClone The biopharmaceutical releases first-quarter financial results. Investors, take note. |
InternetNews
June 20, 2007
Sean Michael Kerner |
Verizon: Lay The Broadband; They Will Come Verizon's Chairman and CEO Ivan Seidenberg is confident that his company's broadband and wireless strategy will win. And he's not afraid of the iPhone. |
The Motley Fool
January 29, 2007
Brian Lawler |
ImClone Fights The Competition The drug developer's performance has been alright, but the competition is heating up. Investors, take note. |
The Motley Fool
September 13, 2007
Brian Lawler |
ImClone Expanding on Erbitux ImClone's turnaround continues with positive results in a cancer study with their lead drug Erbitux. |
The Motley Fool
April 17, 2007
Brian Lawler |
ImClone Loses an Indication ImClone's lead drug fails in a clinical trial. Investors, take note. |
The Motley Fool
October 30, 2007
Brian Lawler |
ImClone Onward Global sales, and excitement about new label expansions for lead drug Erbitux, lift ImClone's third-quarter financial results. |
InternetNews
September 20, 2010 |
Verizon Names McAdam CEO-in-Waiting Verizon Communications clarifies its succession plans by elevating Lowell McAdam from CEO of wireless subsidiary to president and COO of the telecom giant. |
BusinessWeek
January 12, 2004 |
Steve Jobs He has moved beyond computers to establish himself in two businesses where newcomers rarely emerge unscathed: music and movies. |
